Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection.
about
Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysisDrugs for treating Schistosoma mansoni infectionUtility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic reviewEfficacy of praziquantel against Schistosoma mekongi and Opisthorchis viverrini: a randomized, single-blinded dose-comparison trialClinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trialsSingle Versus Double Dose Praziquantel Comparison on Efficacy and Schistosoma mansoni Re-Infection in Preschool-Age Children in Uganda: A Randomized Controlled TrialToward Measuring Schistosoma Response to Praziquantel Treatment with Appropriate Descriptors of Egg ExcretionSustaining control of schistosomiasis mansoni in moderate endemicity areas in western Côte d'Ivoire: a SCORE study protocolSchistosome transmission, water-resource development and altitude in northern Ethiopia.Treatment of intestinal schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy and side-effects, and an extended praziquantel dosing poleSchistosoma mansoni Infections in young children: when are schistosome antigens in urine, eggs in stool and antibodies to eggs first detectable?Accuracy of urine circulating cathodic antigen (CCA) test for Schistosoma mansoni diagnosis in different settings of Côte d'IvoireDexamethasone, a drug for attenuation of Schistosoma mansoni infection morbidityEffect of an armed conflict on relative socioeconomic position of rural households: case study from western Côte d'Ivoire.Drug-based helminth control in Western Pacific countries: a general perspective.Evaluation of a 25-year-program for the control of schistosomiasis mansoni in an endemic area in Brazil.Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.Efficacy of Praziquantel against Schistosoma haematobium in Dulshatalo village, western Ethiopia.Praziquantel efficacy against Schistosoma mansoni among HIV-1 infected and uninfected adults living in fishing villages along Lake Victoria, Northwest TanzaniaInduction of Protective Immune Responses Against Schistosomiasis haematobium in Hamsters and Mice Using Cysteine Peptidase-Based Vaccine.Efficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regionsEfficacy of praziquantel against urinary schistosomiasis and reinfection in Senegalese school children where there is a single well-defined transmission period.New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel.Treatment of schistosomiasis in African infants and preschool-aged children: downward extension and biometric optimization of the current praziquantel dose poleSchistosoma haematobium infections among schoolchildren in central Sudan one year after treatment with praziquantel.Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern EthiopiaEffect of school based treatment on the prevalence of schistosomiasis in endemic area in yemen.Prevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia.A Bayesian approach to estimate the age-specific prevalence of Schistosoma mansoni and implications for schistosomiasis control.Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis.Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire.Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda.Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt.Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis.Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel.The influence of transmission season on parasitological cure rates and intensity of infection after praziquantel treatment of Schistosoma haematobium-infected schoolchildren in Mozambique.Estimating sensitivity of the Kato-Katz technique for the diagnosis of Schistosoma mansoni and hookworm in relation to infection intensity.Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d'Ivoire.
P2860
Q21198915-92AACE22-A7A3-4CAE-882E-045D3EEE8E4BQ24201000-D74BAC76-B547-4B69-975B-21C2D725ED70Q28477145-850F1EC2-0225-40F9-8585-2B95B96DAF7FQ28481492-B810E285-5AB6-4090-B00B-6684376284C2Q28545079-52E2B2EE-94EE-49E2-A607-F94174BC71E8Q28547483-1714CA22-6BC6-4765-840F-F5CDF78E5976Q28548465-CFBD9219-FBFB-4771-8C3B-B87EC58EABE6Q28650345-22ED169C-7016-4A6D-948E-F86EFB6D3038Q30062564-0039B513-ACB1-4B27-B7F4-BC76AB81175DQ33635360-A4931D9E-9540-4BA5-9626-CC9540400277Q33796476-B641547E-2637-4F83-A861-6F8CA59C897AQ34088222-0A13400E-EC48-4576-B696-7E85523E2EFCQ34141949-D55EF889-4248-45BD-B13E-93D09C44D6A8Q34154336-4AC1F236-007C-4D76-924E-5A2B90C73EDCQ34434840-A9B78891-E055-45FC-96FD-60F12D5A5350Q34676884-557DB978-88B5-4EB8-834C-08B6413D7BEFQ34939414-8F740734-393F-423E-8AB5-32151F9B8426Q35001152-BEBB1EAD-7E9C-4EEA-A223-32C5A806E1CBQ35066116-B9C70E5B-BFB1-440B-A380-8DDF0084EC33Q35206686-33B4E692-71DD-45D9-82C9-FEFAD0F87E6FQ35272747-8F037DE3-297A-4C53-B09D-0A570FA7E069Q35834575-93AFC977-4911-444F-B5E4-55B1D7710512Q35905176-B194BED9-0FE2-403D-9151-72F40106464AQ36125948-617CE830-9E19-43A1-A6EB-46804D3481D0Q36209379-1D70C863-8070-48EA-BA59-20D236B829A9Q36441487-DBDB2EEF-C02A-485B-B812-635553B41EC5Q36719660-B95E7602-D3D0-4FD6-A6DF-08E46BF88278Q37046862-615AAD72-31A8-47AA-8B4D-730FC0BE8057Q37360021-411E59AC-1044-4504-A702-67A0E44D8A00Q37373769-1247F002-896C-4AE9-AF08-B94E4B6AA346Q37413446-EBCF2228-9C17-42DC-9B1B-A1F05ED4C10DQ38123553-F2F0BA84-F9E9-47E1-88CF-349E6E09DD7BQ38452685-8D5A8B47-CF78-47C4-98AA-0B5A93B04F72Q38452776-BF21D0EE-71D7-462F-AC96-691C6B237DC6Q38892348-6E0F7A09-3890-4CEF-95B0-7732B84FF457Q38997065-0C1EE9D0-63C8-43E7-B7D8-09E1A1C1B1F0Q39544940-0D62E1DC-48F0-4DB6-82B1-D3F3776AE9A8Q39887622-510D9865-A322-48D0-B1BD-C0EFC8D598E1Q42695873-67E12B42-1F8A-4A20-BCDD-1A5D909AAAFCQ43778585-7CF98BC3-3FB5-4F20-9CEF-C19532AE932D
P2860
Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Efficacy of praziquantel again ...... on for intensity of infection.
@en
Efficacy of praziquantel again ...... on for intensity of infection.
@nl
type
label
Efficacy of praziquantel again ...... on for intensity of infection.
@en
Efficacy of praziquantel again ...... on for intensity of infection.
@nl
prefLabel
Efficacy of praziquantel again ...... on for intensity of infection.
@en
Efficacy of praziquantel again ...... on for intensity of infection.
@nl
P2093
P2860
P1476
Efficacy of praziquantel again ...... on for intensity of infection.
@en
P2093
P2860
P304
P356
10.1046/J.1365-3156.2000.00646.X
P577
2000-11-01T00:00:00Z